Sustained Release of Prostaglandin E1 ... - Semantic Scholar
Recommend Documents
Prostaglandin E1 also increased adenyl cyclase activity and cyAMP levels in anterior pituitary tissue. Although NaF augmented adenyl cyclase activity, it.
Oct 21, 2014 - an antibiotic-eluting graft may provide a better possibility of infection control while maintaining ..... responses, with a different timeline of healing.
Jan 24, 2015 - of ropivacaine effectively blocks neuropathic pain without the induction of analgesic toler- ... model of spinal nerve injury-induced neuropathic pain was selected because it ...... (2006) The bilateral superficial cervical plex-.
Nov 6, 1970 - ROBERT D. Fusco, JAMES B. FmILD, and BERNARD B. DAvIs. From the ..... Abbreviations: CIN, inulin clearance; TRP, per cent tubular phosphate reabsorption; R, right kidney; .... Orloff, J., J. S. Handler, and S. Bergstrom.
Apr 2, 2014 - Institute of Anatomy, Histology and Embryology, University of Veterinary Medicine ... ed poloxamer 407 hydrogel is an effective vehicle for sus-.
of proliferation cells involves diminished efficacy of prostaglandin E1-mediated inhibition. Effector function for RAS oncogene in interleukin-3-dependent myeloid.
3. Schneider R: Doxycycline esophageal ul- cers. Am J Dig Dis 1977; 22: 805-807. 4. ... Three days later the patient became .... familial (M. Grace: personal com-.
Sustained Release of Prostaglandin E1 ... - Semantic Scholar
Yoshio Arai, MD; Keiichi Hirose, MD; Shyamal Chandra Bir, MD;. Hisanori Horiuchi ..... Marui A, Tabata Y, Kojima S, Yamamoto M, Tambara K, Nishina T, et al.
Circ J 2008; 72: 1693 – 1699
Sustained Release of Prostaglandin E1 Potentiates the Impaired Therapeutic Angiogenesis by Basic Fibroblast Growth Factor in Diabetic Murine Hindlimb Ischemia Yuhong Huang, MD¶; Akira Marui, MD¶; Hisashi Sakaguchi, MD; Jiro Esaki, MD; Yoshio Arai, MD; Keiichi Hirose, MD; Shyamal Chandra Bir, MD; Hisanori Horiuchi, MD*; Takayuki Maruyama, PhD**; Tadashi Ikeda, MD; Yasuhiko Tabata, PhD†; Masashi Komeda, MD Background Basic fibroblast growth factor (bFGF) is a potent mitogen; however, diabetes mellitus might impair its angiogenic property. Prostaglandin E1 (PGE1) is a potent vasodilator and improves endothelial function. Thus, PGE1 could potentiate the angiogenic properties of bFGF in patients with diabetes mellitus. Methods and Results Streptozotocin-induced diabetic mice with unilateral hindlimb ischemia were randomly treated as follows: no treatment, 0.2μg of PGE1, 10μg of bFGF, and combined administration of PGE1 and bFGF. Blood perfusion was evaluated by the ratio of ischemic- to normal-limb blood perfusion. Four weeks after the treatment, the combined administration of bFGF and PGE1 increased the blood perfusion ratio as compared with single bFGF or PGE1 (77±10% vs 56±10% and 58±10%; p
